KelSie Biotech Closes First Tranche of $5 Million Series A Round to expand its Unique Drug Delivery Intellectual Property Portfolio and Expand Market Penetration

Friday, May 31, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Innovative Biotech Company Announces Research and Market Expansion Plans

BOULDER, Colo., May 31, 2019 /PRNewswire-PRWeb/ -- KelSie Biotech, announced today that it has closed the first tranche

of $5 million in Series A funding. The investment round, led by Salveo Capital, a leading cannabis focused investment firm, with participation from LA-based Arcadian Capital and other investors, will support the company's scientific research and market expansion.

KelSie Biotech creates high bioavailability delivery methods for active pharmaceutical ingredients in the medical, nutraceutical and CBD/cannabis fields. KelSie licenses its patented and proprietary technologies which are based on novel particle morphology science and include dry-inhaled powder and true sublingual delivery systems. The dry-inhaled powder technology successfully completed Phase I Clinical Trials for delivery of a stable measles vaccine.

"KelSie is delighted to partner with Salveo and our other investors to bring effective and convenient drug and supplement delivery methods to more consumers," said Cameron Keluche, KelSie Co-Founder. "We are committed to revolutionizing the delivery of cannabinoids and other drugs with superior bioavailability. Having experienced partners like Salveo and Arcadian is invaluable."

"We constantly look for new and innovative technology that drives consumption patterns and introduces healthier and more discreet form factors across the pharmaceutical industry," said Jeffrey Howard, a Managing Partner at Salveo Capital. "We are impressed with KelSie's strong patented and proprietary technology, including their true sublingual delivery systems with quick onset times. The Company's focus on micro-dosing is another key differentiator that will continue to attract new demographics of cannabis/CBD consumers focused on low-dose health and wellness. We couldn't be more excited to be working with the entire KelSie team to continue the company's strong momentum."

Historically, the most common method for administering medications and supplements has been oral or injection. But the gastrointestinal tract degrades the efficacy of pills and liquids before they reach the bloodstream and there are many complications to syringe-based methods. KelSie's patented breakthrough delivery methods revolutionize drug delivery for a wide range of applications.

Most recently, the technology has been successfully commercialized under the SUM Microdose brand, licensed to State Operators producing fast-acting, water-soluble CBD/cannabis sublingual tablets. As SUM Microdose approaches its first successful year of sales in Colorado, the roll-out has begun across other states through licensing to additional State Operating Partners.

"Our consumer brand strategy is focused on investing in companies that truly add value to the consumption experience and have a high degree of commercial scalability. We believe that the KelSie's core technologies provide a framework for the mainstream adoption of cannabinoid-based medicines," said Krishnan Varier, Managing Partner of Arcadian Capital Management.

About KelSie Biotech KelSie Biotech creates high bioavailability delivery methods for active pharmaceutical ingredients in the medical, nutraceutical and CBD/cannabis fields. The genesis of the technology came from Dr. Robert Sievers, who created an inhalable, needle-free measles vaccine that didn't require refrigeration. Sievers received a $20 million, 5-year grant funded by the Bill and Melinda Gates Foundation to develop a measles vaccine that could be used effectively in rural regions lacking medical infrastructure. The first brand to deploy KelSie's technology is SUM Microdose, water-soluble sublingual CBD/cannabis tablets. For more information, please visit http://www.kel-sie.com

About Salveo Capital Launched at the end of 2016, Salveo Capital is an alternative investment firm specializing in the legalized cannabis space, particularly ancillary businesses. Salveo Capital's approach is to bring an institutional quality discipline to company vetting, investment structures and portfolio management. The Firm is committed to shaping the early-stage, yet rapidly growing, industry by providing funding and development to companies with the will and vision to be the future faces of legalized marijuana. As cannabis legalization spreads, Salveo Capital seeks to build long term sustainable companies and support innovative technologies, products and services to help address the unique requirements of the industry. The firm is based in Northbrook, Illinois, and with vertical industry executives and cannabis operating advisors across the country, including key markets of California and Colorado. For more information, please visit http://www.salveocapital.com.

SOURCE KelSie Biotech



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store